NEW YORK, Feb. 6, 2014 /PRNewswire/ -- S&P Capital IQ announced today that it has commenced Standard & Poor's Factual Stock Report coverage on Wellness Center USA Inc.
Wellness Center USA (OTCQB: WCUI) is a healthcare and medical device solutions company that addresses important healthcare and wellness needs. The company started out as an online nutraceutical store but has expanded into additional businesses within the healthcare and medical sectors through two acquisitions (both completed in August 2012), CNS Wellness Florida, LLC (CNS) and Psoria-Shield Inc. (PSI). CNS is a cognitive neuroscience company specializing in the treatment of brain-based behavioral health disorders including developmental, emotional and stress-related problems. PSI is a developer and manufacturer of "Targeted" ultraviolet (UV) phototherapy devices for the treatment of skin diseases such as psoriasis, eczema, vitiligo, and others.
The company believes that CNS treatment modalities, when combined in specific manners that are proprietary to CNS, contribute to restoring the brain's ability to regulate itself within normative limits. According to the company, CNS methods are noninvasive and safe, and achieve their goals without the use of prescription pharmaceuticals. This technology helps the client to overcome difficulties with mental health and/or developmental barriers to successful daily functioning, and thereby to experience a higher quality of life. CNS has serviced over 600 clients since commencement of operations in 2009.
PSI, a medical device design and manufacturing company, designs, develops and markets a targeted UV phototherapy device called the Psoria-Light. The Psoria-Light is designated for use in targeted PUVA photochemistry and UVB phototherapy and is designed to treat certain skin conditions including psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis, and leukoderma. Psoria-Shield manufactures the Psoria-Light under an ISO 13485 quality system at its headquarters in Tampa, FL.
The Psoria-Light consists of three components: a base console, a color display with touchscreen control, and a hand-held delivery device with a conduit (or tether) between the handheld device and the base console. PSI received FDA clearance for the Psoria-Light on February 11, 2011 and was granted permission to affix the CE mark for the Psoria-Light in the fourth quarter of 2011. PSI has serviced approximately 200 clients since PSI began selling the device in January 2012. Since the CNS and PSI acquisitions, Wellness Center USA has focused mainly on development of CNS and PSI products, services and operations. The company has continued limited development of its aminofactory.com web-based online store and expansion of a wider range of nutritional supplements.
On January 28, 2014, Wellness Center USA announced the signing of an agreement to acquire National Pain Centers, Inc (NPC), a Nevada corporation based in Illinois that focuses on diagnosis, treatment, research, advocacy, education, and setting standards and protocols within interventional and multi-modal pain management.
Wellness Center USA, Inc. is based in Schaumburg, Illinois.
S&P Capital IQ's Factual Stock Report coverage on Wellness Center USA Inc. will also be accessible on an ongoing basis to the investment community by scores of buy-side institutions and sell-side firms that utilize S&P Capital IQ research and information platforms daily. Millions of self-directed investors also have access to the report via their e-brokerage accounts. Please visit www.wellnesscenterusa.com for additional information.
About S&P Capital IQ's Factual Stock Reports
Currently profiling approximately 500 issuers, Standard & Poor's Factual Stock Reports, produced by S&P Capital IQ, increase market awareness of issuers in the investment community with insightful commentary and key statistics and information. Standard & Poor's Factual Stock Reports provide factual research coverage about company fundamentals and business prospects, thereby enabling information about covered companies to reach a wide investor audience of Buy and Sell-side investors. Updated weekly with the latest pricing, trading volume, and other data, the reports include recent developments, a financial review, key operating information, industry and peer comparisons, institutional holdings analysis, Street Consensus and opinions, performance charts, business summary, fundamental data, and news. Because coverage of these reports is underwritten by the issuer, S&P Capital IQ does not offer investment opinions concerning the advisability of investing in these stocks.
Standard & Poor's Factual Stock Reports are produced separately from any other analytic activity of S&P Capital IQ or related organizations. S&P Capital IQ does not trade on its own account.
About S&P Capital IQ
S&P Capital IQ, a part of McGraw Hill Financial, is a leading provider of multi-asset class and real time data, research and analytics to institutional investors, investment and commercial banks, investment advisors and wealth managers, corporations and universities around the world. Evaluated pricing is prepared by Standard & Poor's Securities Evaluations, Inc., a part of S&P Capital IQ and a registered investment adviser with the U.S. Securities and Exchange Commission. In the United States, research reports are prepared by Standard & Poor's Investment Advisory Services LLC, a part of S&P Capital IQ and a registered investment adviser with the U.S. Securities and Exchange Commission. S&P Capital IQ provides a broad suite of capabilities designed to help track performance, generate alpha, and identify new trading and investment ideas, and perform risk analysis and mitigation strategies. Through leading desktop solutions such as the S&P Capital IQ, Global Credit Portal and MarketScope Advisor desktops; enterprise solutions such as S&P Capital IQ Valuations; and research offerings, including Leveraged Commentary & Data, Global Markets Intelligence, and company and funds research, S&P Capital IQ sharpens financial intelligence into the wisdom today's investors need. For more information visit: www.spcapitaliq.com.
SOURCE S&P Capital IQ